Hepatitis C Virus Medicines

Product Details:

Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved.

Product Details:

• Sofosbuvir 400 mg Velpatasvir 100 mg Tablets is the global oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. VELPANAT is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated). In those with advanced cirrhosis (decompensated), VELPANAT is used with ribavirin.

Therapeutic indications

• Velpanat is indicated for the treatment of adult patients with chronic Hepatitis C Virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections
• With or without cirrhosis or with compensated cirrhosis
• With decompensated cirrhosis for use in combination with Ribavirin

 

Product Details:

Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus genotype 1. Some evidence also supports use in HCV genotype 3 and 4.

Additional Information:

• Packaging Details: 28 Tablets in a bottle

Product Details:

Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus genotype 1. Some evidence also supports use in HCV genotype 3 and 4.

Additional Information:

• Packaging Details: 28 tablets in a bottle

Product Details:

Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six.